title: [Psychoactive drugs and costs in the Madrid III (Valdemoro) prison].
abstract: Annual pharmaceutical expenditures in prisons increases dramatically and the rising costs of psychoactive drugs have especially contributed to this. These drugs are often prescribed in order to find therapeutic uses in the field of personality disorders, addictions, and dysfunctional behaviours that are not included in the authorized indications (compassionate use). This study has enabled a detailed description of the use of psychoactive drugs at the Madrid III prison, a centre with one of the lowest levels of pharmaceutical expenditure in this autonomous community. During a two-week period, all prescriptions of psychoactive drugs were collected and registered along with data of several possible conditioning factors. 20.5% of the population was receiving some kind of psychoactive drug; 76% of those inmates undergoing treatment were receiving one or two substances; 65% were taking anxiolytics, 38% antidepressants and 27% antipsychotics. The total amount of psychoactive drugs consumed was 9,840 defined daily doses, 46% of which were anxiolytics, 17% antidepressants and 14% antipsychotics. The total cost of the fortnight's treatment was euros 5,379 with a saving of euro 611 due to requesting and selecting offers carried out by the pharmacist. 72% of the costs were spent on anti-psychotics and the newer psychoactive drugs, representing 66% of the prescriptions, accounted for 98% of expenditure. The prescriber was one of the key influential factors over the amount, type and cost of the treatments. There are signs that compassionate use of current antipsychotics and antiepileptics, and newer antidepressants are a main cause of the dramatic increase in the costs, with cost-efficiency not always clearly demonstrated. These results are not an isolated fact restricted only to prisons, as demonstrated by consumption data published by the National Health System in the same year.
authors.affiliation: Centro Penitenciario Madrid III, Madrid, España.
authors.forename: I
authors.initials: I
authors.lastname: Algora-Donoso
authors.forename: O
authors.initials: O
authors.lastname: Varela-González
mesh_terms: D003365:Costs and Cost Analysis; D003430:Cross-Sectional Studies; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics*; D011330:Prisons; D011619:Psychotropic Drugs / Q000191:economics*
chemical_list: D011619:Psychotropic Drugs